
Wegovy
ProductHeard on podcasts recently
Wegovy is a brand name for semaglutide, an anti-obesity medication developed by Novo Nordisk for chronic weight management. Administered as a weekly subcutaneous injection, it acts as a GLP-1 receptor agonist to regulate appetite and food intake.
Rank this week
—
Not in this week’s list
Share of the conversation
—
Reach this week
—
Tone this week
—
Not enough signal yet (fewer than 3 episodes scored).
Share of the conversation
Mentions of Wegovy per 1,000 mentions of anything, 7-day rolling, all podcasts.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 21 | 0.02‰ | 1 |
| Sep 22 | 0.02‰ | 1 |
| Sep 25 | 0.03‰ | 1 |
| Sep 28 | 0.03‰ | 1 |
| Oct 1 | 0.03‰ | 1 |
| Oct 3 | 0.03‰ | 1 |
| Oct 6 | 0.03‰ | 1 |
| Oct 8 | 0.03‰ | 1 |
| Oct 10 | 0.03‰ | 1 |
| Oct 11 | 0.03‰ | 1 |
| Oct 12 | 0.04‰ | 1 |
| Oct 16 | 0.04‰ | 2 |
| Oct 20 | 0.06‰ | 5 |
| Oct 21 | 0.07‰ | 1 |
| Oct 22 | 0.08‰ | 2 |
| Oct 23 | 0.11‰ | 5 |
| Oct 27 | 0.07‰ | 1 |
| Oct 28 | 0.08‰ | 2 |
| Oct 29 | 0.08‰ | 1 |
| Nov 1 | 0.05‰ | 2 |
| Nov 2 | 0.06‰ | 1 |
| Nov 4 | 0.04‰ | 1 |
| Nov 5 | 0.04‰ | 1 |
| Nov 8 | 0.03‰ | 1 |
| Nov 10 | 0.03‰ | 1 |
| Nov 15 | 0.02‰ | 1 |
| Nov 16 | 0.02‰ | 1 |
| Nov 17 | 0.03‰ | 2 |
| Nov 18 | 0.04‰ | 1 |
| Nov 19 | 0.05‰ | 1 |
Who is saying what about Wegovy
Verified quotes from the last 90 days: who made the most claims, and which way they leaned.
- Emily Milliron1 claim on 1 show
“expanding to younger children could help Novo fend off its key rival, Eli Lilly.”
Brew Markets · Nov 16 ↗ - John Certeau1 claim on 1 show
“Wagovi's next frontier for growth may be children.”
Brew Markets · Nov 16 ↗
Discussed alongside
Names that come up in the same conversations as Wegovy.
Embed this
Paste this on your site to show Wegovy's current trend:
<iframe src="https://podlume.ai/embed/e/wegovy" width="360" height="220" style="border:0" loading="lazy" title="Wegovy on PodLume Trends"></iframe>